로딩 중…
지수 로딩 중…
Entrada Therapeutics, Inc.
TRDA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$7.26+6.92%
2026-08-03
Financials
Valuation Metrics
Entrada Therapeutics, Inc.'s Market Cap is $282M. At end of 2025 it was $425M. Ranked #2972 of 3,112 in US market (top 96%), #1338 of 1,445 on NASDAQ (top 93%), #245 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 91%) by Market Cap.
Investment Metrics(as of 2026-08-03)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $282M | US#2,972/3,112 Sec#245/269 |
| Revenue | $6M | US#2,936/3,112 Sec#188/269 |
| Net Income | $-166M | US—/3,112 Sec—/269 |
| Total Assets | $336M | US#2,866/3,112 Sec#197/269 |
| Net Assets | $271M | US#2,609/3,112 Sec#171/269 |
| Value | ||
| P/B | 1.04x | US#371/3,112 Sec#16/269 |
| P/S | 49.12x | US#2,876/3,112 Sec#168/269 |
| FCF Yield | -46.71% | US—/3,112 Sec—/269 |
| Profitability | ||
| ROE | -61.33% | US#2,777/3,112 Sec#190/269 |
| ROA | -49.51% | US#2,965/3,112 Sec#217/269 |
| Op. Margin | -3109.29% | US#2,941/3,112 Sec#186/269 |
| Revenue Growth | -95.74% | US#2,937/3,112 Sec#184/269 |
| Earnings Growth | -319.04% | US#2,284/3,112 Sec#87/269 |
| Financial Health | ||
| Debt Ratio | 23.87% | US#253/3,112 Sec#83/269 |
| Total Debt | $50M | US#2,548/3,112 Sec#147/269 |
| FCF | $-132M | US#2,650/3,112 Sec#177/269 |
| Cash | $76M | US#2,362/3,112 Sec#197/269 |
| Current Ratio | 13.90x | US#176/3,112 Sec#58/269 |
| Performance | ||
| 1Y Return | 25.17% | US#1,393/3,112 Sec#159/269 |
| 1M Return | -5.96% | US#2,326/3,112 Sec#131/269 |
| From 52W High | -55.87% | US#2,877/3,112 Sec#233/269 |
| 1Y MDD | -64.75% | US#2,826/3,112 Sec#231/269 |
| Trading | ||
| Volume | 494,203 shares | US#2,085/3,112 Sec#202/269 |
| Trading Value | $3M | US#2,773/3,112 Sec#228/269 |
| Per Share | ||
| EPS | $-3.47 | US—/3,112 Sec—/269 |
| BPS | $7.40 | US#1,997/3,112 Sec#95/269 |